4CPS-057 Dalbavancina and tedizolid: adequate alternatives for strains with reduced sensitivity to vancomycin, daptomycin or linezolid?

BACKGROUND: We ask if dalvabancina and tedizolid are good alternatives for strains with reduced sensitivity to vancomycin, daptomycin or linezolid. PURPOSE: To determine the most cost-effective treatment option for GRAM +microorganisms with reduced sensitivity to vancomycin, linezolid or daptomycin,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Hosp Pharm
Auteurs principaux: Navarro, M, Betancor, T, Tévar, E, Calzado, G, Suárez, M, Plasencia, I, Ramos, E, Gómez, E, Ferrer, A, Vera, M, Merino, J
Format: Artigo
Langue:Inglês
Publié: BMJ Group 2018
Sujets:
Section 4: Clinical pharmacy services
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535377/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.148
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires